ADMA Biologics (ADMA) Competitors

ADMA Biologics (NASDAQ:ADMA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Do insiders & institutionals have more ownership in ADMA or ACAD?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk and volatility, ADMA or ACAD?

ADMA Biologics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Do analysts recommend ADMA or ACAD?

ADMA Biologics currently has a consensus price target of $27.67, suggesting a potential upside of 55.43%. ACADIA Pharmaceuticals has a consensus price target of $28.88, suggesting a potential upside of 12.18%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
ACADIA Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Does the media refer more to ADMA or ACAD?

In the previous week, ADMA Biologics had 1 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 12 mentions for ADMA Biologics and 11 mentions for ACADIA Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.59 beat ACADIA Pharmaceuticals' score of 0.94 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	12 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ACADIA Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ADMA or ACAD more profitable?

ADMA Biologics has a net margin of 44.06% compared to ACADIA Pharmaceuticals' net margin of 21.80%. ADMA Biologics' return on equity of 41.01% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	44.06%	41.01%	28.47%
ACADIA Pharmaceuticals	21.80%	14.69%	9.41%

Which has preferable valuation & earnings, ADMA or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	9.96	$197.67M	$0.86	20.70
ACADIA Pharmaceuticals	$957.80M	4.53	$226.45M	$1.33	19.35

Summary

ADMA Biologics beats ACADIA Pharmaceuticals on 9 of the 16 factors compared between the two stocks.